These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37423481)

  • 1. Real world validation of an adjunctive gene expression-profiling assay for melanoma diagnosis and correlation with clinical outcomes at an academic center.
    Boothby-Shoemaker W; Guan L; Jones B; Chaffins M; Kohen L; Pimentel J; Veenstra J; Friedman BJ
    Hum Pathol; 2023 Sep; 139():73-79. PubMed ID: 37423481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Genetic Expression Profiles in Melanoma Diagnosis.
    Leachman SA; Mengden Koon S; Korcheva VB; White KP
    Dermatol Clin; 2017 Oct; 35(4):537-544. PubMed ID: 28886810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations.
    Casillas AC; Muhlbauer A; Barragan VA; Jefferson I; Speiser JJ
    Am J Dermatopathol; 2024 Mar; 46(3):137-146. PubMed ID: 38354382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between histologic assessment and fluorescence in situ hybridization using MelanoSITE in evaluation of histologically ambiguous melanocytic lesions.
    Zembowicz A; Yang SE; Kafanas A; Lyle SR
    Arch Pathol Lab Med; 2012 Dec; 136(12):1571-9. PubMed ID: 22480223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
    Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
    Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
    Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
    Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms.
    Reimann JDR; Salim S; Velazquez EF; Wang L; Williams KM; Flejter WL; Brooke L; Sunder S; Busam KJ
    Mod Pathol; 2018 Nov; 31(11):1733-1743. PubMed ID: 29955141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
    Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
    JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision.
    Laar RV; King S; McCoy R; Saad M; Fereday S; Winship I; Uzzell C; Landgren A
    Biomark Med; 2021 Sep; 15(13):1111-1122. PubMed ID: 34184547
    [No Abstract]   [Full Text] [Related]  

  • 10. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
    Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
    J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Physician's Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms.
    Marks E; Jarell A; Ludzik J; Farberg AS; Rabinovitz HS; Phelps RG; Cockerell CJ; Witkowski A
    J Clin Aesthet Dermatol; 2023 Apr; 16(4):12-20. PubMed ID: 37077930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes.
    Ko JS; Matharoo-Ball B; Billings SD; Thomson BJ; Tang JY; Sarin KY; Cai E; Kim J; Rock C; Kimbrell HZ; Flake DD; Warf MB; Nelson J; Davis T; Miller C; Rushton K; Hartman AR; Wenstrup RJ; Clarke LE
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1107-1113. PubMed ID: 28377414
    [No Abstract]   [Full Text] [Related]  

  • 13. Observational Study Examining the Diagnostic Practice of Ki67 Staining for Melanocytic Lesions.
    Vyas NS; Charifa A; Desman GT; Goldberg M; Singh R; Phelps RG; McNiff JM
    Am J Dermatopathol; 2019 Jul; 41(7):488-491. PubMed ID: 31233404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
    Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
    Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center.
    Shoo BA; Sagebiel RW; Kashani-Sabet M
    J Am Acad Dermatol; 2010 May; 62(5):751-6. PubMed ID: 20303612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of reflectance confocal microscopy and gene expression profiling for melanocytic lesions with uncertain malignant potential: A case series.
    Gronbeck C; Rabinovitz H; Np MO; Grant-Kels JM
    J Cutan Pathol; 2023 Jul; 50(7):623-628. PubMed ID: 36944578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
    Clarke LE; Warf MB; Flake DD; Hartman AR; Tahan S; Shea CR; Gerami P; Messina J; Florell SR; Wenstrup RJ; Rushton K; Roundy KM; Rock C; Roa B; Kolquist KA; Gutin A; Billings S; Leachman S
    J Cutan Pathol; 2015 Apr; 42(4):244-52. PubMed ID: 25727210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.
    Kashani-Sabet M; Leachman SA; Stein JA; Arbiser JL; Berry EG; Celebi JT; Curiel-Lewandrowski C; Ferris LK; Grant-Kels JM; Grossman D; Kulkarni RP; Marchetti MA; Nelson KC; Polsky D; Seiverling EV; Swetter SM; Tsao H; Verdieck-Devlaeminck A; Wei ML; Bar A; Bartlett EK; Bolognia JL; Bowles TL; Cha KB; Chu EY; Hartman RI; Hawryluk EB; Jampel RM; Karapetyan L; Kheterpal M; Lawson DH; Leming PD; Liebman TN; Ming ME; Sahni D; Savory SA; Shaikh SS; Sober AJ; Sondak VK; Spaccarelli N; Usatine RP; Venna S; Kirkwood JM
    JAMA Dermatol; 2023 May; 159(5):545-553. PubMed ID: 36920356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Affecting Dermatologists' Use of a 31-Gene Expression Profiling Test as an Adjunct for Predicting Metastatic Risk in Cutaneous Melanoma.
    Svoboda RM; Glazer AM; Farberg AS; Rigel DS
    J Drugs Dermatol; 2018 May; 17(5):544-547. PubMed ID: 29742186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue.
    Koh SS; Opel ML; Wei JP; Yau K; Shah R; Gorre ME; Whitman E; Shitabata PK; Tao Y; Cochran AJ; Abrishami P; Binder SW
    Mod Pathol; 2009 Apr; 22(4):538-46. PubMed ID: 19270649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.